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IMMUNOFLUORESCENCE ASSAY REACTIVITY PATTERNS OF SERUM SAMPLES
PRESENTING INDETERMINATE WESTERN BLOT RESULTS FOR ANTIBODIES TO
HIV-1 AND HTLV-I/II IN CORDOBA, ARGENTINA
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SUMMARY
Serum samples (n: 110) from blood donors and high risk individuals from Cordoba, Argentina with indeterminate HIV-1 and
HTLV-I/II Wb profiles were studied for specific antibodies to HTLV-I/II and HIV-1 by indirect immunofluorescence assay (IFA) and
for the presence or absence of HIV-1 and HTLV-I/II specific bands by Wb. This study was carried out in order to characterize their
putative reactions with HIV-1 and HTLV-I/II proteins and to resolve the retrovirus infection status of these individuals. Results
indicated that blood donors sera displaying indeterminate HIV-1 or HTLV-I/II Wb patterns were not immunoreactive to HTLV-I/II
and HIV-1 on IFA. However, a high rate of indeterminate HIV-1 and HTLV-I/II Wb samples from high risk individuals had positive
HTLV-I/II and HIV-1 IFA results respectively. Our study supports the growing evidence that HTLV-HIV indeterminate seroreactivity
in low risk population is due to a cross reaction against nonviral antigens, and in high risk populations the indeterminate samples
show serological cross-recognition between HIV-1 proteins and HTLV-I/II proteins on Wb. These results point out the necessity to
investigate the HTLV-I/II reactivity in indeterminate HIV-1 samples and viceversa in order to confirm the diagnosis. Finally, this
study shows the potential usefulness of IFA in elucidating the status of HIV-1 and HTLV-I/II infection of individuals with indeterminate
Wb profiles, thus enabling resolution of retrovirus infection status.
KEYWORDS: Retroviruses; HIV-1; HTLV-I/II; Confirmatory testing; Indeterminate results; Western blot; Indirect immunofluorescence
assay.
INTRODUCTION
Standard practice for HIV-1 and HTLV-I/II antibodies testing in most
laboratories involves initial screening and retesting of reactive sera by
ELISA or Particle agglutination (PA) followed by Western blot (Wb)
confirmation.
Indeterminate patterns on Wb are common in non HIV-1 or non
HTLV-I/II infected people11. The proportion of repeatedly anti-HIV-1
and anti-HTLV-I/II samples reactive by ELISA but with indeterminate
Wb patterns has been a subject of concern in the face of reports that
range from 13% to 48% and 0.02% to 0.03% respectively, among blood
samples from United States donors12,18.
An increasing number of indeterminate results were observed with
a higher severity of HIV-related diseases16. This increased occurrence of
indeterminate results concomitant with the severity of clinical disease is
most likely accountable for the well-described phenomenon of declining
titers of antibodies to HIV-1 gag and pol antigens with progression of
disease1,5,10.
The HIV-p24 band, the most commonly observed in indeterminate
Wb analyses13,19 is present in 50-70% of indeterminate Wb, and the only
one present in 50% of indeterminate sera17. These gag-reactive antibodies
are often a source of false-positive screening ELISA resulting in
indeterminate Wb. In many cases, the indeterminate status of a patient
will be resolved by the time when a second specimen is tested 3 to 6
months later11.
However, the patterns of patients sera with core protein p24 or p24/
p55 reactivity on Wb for HIV-1 tend to remain indeterminate over a
period of many months thereby leaving in limbo the individuals tested
and resulting in anxiety and delay in treatment of infected individuals21.
The env-reactive indeterminate tests for HIV-1 are about 10 times
less frequent than the gag-reactive indeterminate test, among blood donors
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in the United States18. Moreover, among volunteer blood donors
indeterminate HTLV serologic test results, mostly gag reactive, are found
at least as frequently as HTLV-seropositive results12.
Another issue of retrovirus serologic diagnosis is the observation of
ELISA-negative samples with indeterminate Wb patterns also has been
a matter of concern, since reports of such results are found in as much as
20% of ELISA-negative HIV-1 blood donors in the United States18, and
in 11% of ELISA-negative for HTLV-I/II in the Netherlands23.
The rationale for these phenomena is unknown. It is possible that
indeterminate reaction patterns are caused by antibodies directed against
nonviral antigens originating from the cells in which HIV-1 or HTLV-I/
II are propagated. Cross reaction against unknown HIV-1 and HTLV-I/
II related viruses is another possibility22.  Alternatively, antibodies reactive
only to gag products could be the first evidence of seroconversion after
an individual being exposed to and infected with HIV-1 or HTLV-I/II.
The clinical and transfusional importance of these indeterminate Wb
results are poorly understood in populations generally considered of
low risk2.
 To better understand the implication of the high frequency of
retrovirus indeterminate findings and to provide the individuals with
most appropriate information, serum samples from Argentinian blood
donors and high risk individuals who had indeterminate HIV-1 and
HTLV-I/II Wb profiles were studied for specific antibodies to HTLV-I/II
and HIV-1 by indirect immunofluorecence assay (IFA) and for the
presence or absence of HIV-1 and HTLV-I/II specific bands on Wb.
MATERIALS AND METHODS
1. Samples. A total of 110 serum samples corresponding to
populations at different risk from Cordoba, Argentina were analyzed
(Tables 1 and 2).
2. Serological assays.
2.1 Screening test: Enzyme immuno assays: Vironostika HIV Uni-
Form plus O, Organon Teknika and Vironostika HTLV-I/II, Organon
Teknika; Particle agglutination assay: Serodia HTLV-I (Fujirebio Inc.,
Tokyo, Japan) were used according to the manufacturers instructions.
2.2 Confirmatory test: Western blot assay: NOVA PATH HIV-1
IMMUNOBLOT BIO-RAD, USA and Bioblot HTLV, Biokit S.A., Spain;
were used according to the manufacturers instructions. “In house” indirect
immunofluorescence assay (IFA): slides prepared with HTLV-I
transformed human T cell line (MT-2) and HIV-1 infected H9-IIIB cells
were used as source of antigens. IFA was performed according to the
procedure previously described by GALLEGO et al.7,8.
3. Positivity criteria for HTLV-I/II and HIV-1 antibody detection.
Sera were considered positive for HIV-1 or HTLV-I/II antibodies on
IFA when characteristic cytoplasmic staining on infected cells and no
IFA staining on uninfected cell lines were observed.
A specimen with reactivity on Western blot both to env encoded
glycoprotein and gag encoded protein was considered positive for HIV-
1 or HTLV-I/II antibodies. A specimen was considered indeterminate if
it showed any other patterns that did not meet the positivity criteria
recommended by the manufacturer, and negative if it showed no antibody
reactivity.
Table 2
Summary of HIV-1 and HTLV-I/II indeterminate Western blot profiles of the
sera studied
Group n Western blot band *
HIV-1 (NOVA HTLV-I/II (Bioblot
PATH HIV-1 HTLV Biokit, SA,
IMMUNOBLOT Barcelona, Spain).
BIO-RAD)
A (n: 11) 1 p65, p24
1 p55, p24
8 p24
1 gp 160
B (n: 50) 31 p24
9 gp 160
6 p18, p24
1 p18
1 p18, p65
2 gp 120, gp 160
D (n: 7) 5 p19
2 rgp 46II, rgp 21
E (n: 13) 9 p19
1 p24, p28
1 p19, p28
1 p24
1 p24, p19
F (n: 8) 1 p53, p24, p19
1 p24, p19
1 p53, p19
5 p19
*For band, p denotes protein, gp denotes glycoproteins, rgp denotes recombinant
glycoproteins.
Table 1
Characteristics of the populations studied: risk and serological status
 Group  N  Population Serological status
HIV-1 HTLV-I/II
EIA Wb PA Wb
A 11 Healthy blood donors R I
B 50 High risk for infection* R I
C 21 Healthy blood donors R N
D 7 High risk for infection* R I
E 13 Healthy blood donors R I
F 8 Healthy blood donors N I
*: Homosexual men, heterosexual, intravenous drug users, sex workers,
hemophiliacs and polytransfused individuals; I: indeterminate; R: reactive; N:
negative; EIA: enzyme immuno assay, PA: particle agglutination, Wb: Western
blot.
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Six (12%) of the 50 individuals at high risk for infection (group B)
with indeterminate HIV-1 Wb were positive for HTLV-I/II and HIV-1
by IFA (Table 3); 13 (26%) were positive only for HTLV-I/II by IFA, 6
(12%) showed positive reactivity to HIV-1 only, and 25 (50%) were
negative for HTLV-I/II and HIV-1 by IFA (Table 3).
The 13 healthy blood donors of group E resulted negative for HIV-
1 by IFA and Wb, while 6 (86%) of the 7 individuals at high risk of
infection (group D) were positive for HIV-1 by IFA and one was positive
for HTLV-I/II and HIV-1 by IFA (Table 4). Eight blood donors with
negative anti-HTLV-I/II screening and indeterminate Wb results (group
F) had negative HTLV-I/II and HIV-1 IFA results (Table 4).
DISCUSSION
Human T lymphotropic virus and HIV-1 indeterminate serologic
results are commonly found in Wb confirmatory testing. The causes of
these reactions, however, remain unsettled.
Blood donors with such serologic reactions are usually rejected for
blood donation and there is uncertainty as to what they should be told
and how they should be counseled.
Results of the study presented here indicate that most of the blood
donors sera that display indeterminate HIV-1 Western blot patterns are
not immunoreactive to HTLV-I/II and HIV-1 on IFA, suggesting that
this pattern of reactivity is not indicative of HIV-1 or HTLV-I/II infection
(Table 3). However, a high rate (26%) of indeterminate HIV-1 Wb samples
from high risk individuals evidenced positive HTLV-I/II IFA results while
12% tested positive on IFA for both HIV-1 and HTLV-I/II, indicating
that these individuals are coinfected with both viruses (Table 3).
The absence of reactivity against HIV-1 and HTLV-I/II on IFA of
blood donors samples with indeterminate HTLV-I/II patterns indicated
that this seroreactivity is unlikely to be due to HTLV-I/II or HIV-1
infection (Table 4). Moreover, the high number (86%) of HIV-1 Wb
positive results among high risk individuals with HTLV-I/II Wb
indeterminate results strengthen the HIV-1-infected status of these
individuals (Table 4).
In summary, we postulate that indeterminate HIV-1 and HTLV-I/II
Wb patterns in the studied low and high risk populations could be
interpreted as it is shown in figures 1 and 2. Our study supports the
growing evidence that HTLV-HIV indeterminate seroreactivity in low
risk population is due to a cross-reaction against nonviral antigens
originating from the cells in which these retroviruses are propagated
(Fig. 1 and 2). This interpretation criterion is compatible with that of
other authors 6,9,12,22,23.  Antibodies to p24, gp 120 and gp 160 HIV antigens
have been shown to cross-react with human platelets21. In addition, certain
monoclonal antibodies against HTLV-I p19 have been demonstrated to
recognize unique cellular antigens14. Cross-reaction against unknown
related retrovirus is another possibility.
The non-specificity of HTLV-I/II indeterminate Wb results in low
risk populations was confirmed since the serum samples from eight
individuals of group F that were negatives on anti-HTLV-I/II screening
test and Wb indeterminate, presented negative reaction for HIV-1 and
HTLV-I/II by means of IFA (Table 4).
Table 3
HTLV-I/II antibodies in individuals with indeterminate or negative
HIV-1 Wb status
Group n (%) IF antibodies
HTLV-I/II (MT-2)* HIV-1 (H9 IIIb)**
A (n: 11) 10 (91%) - -
Healthy blood 1 (9%) - +
donors
B 6 (12%) + +
(n: 50) 6 (12%) - +
High risk 13 (26%) + -
for infection 25 (50%) - -
C 19 (90.5%) - -
(n: 21)
Healthy blood 2 (9.5%) - +/-
donors
+: Positive; +/-: Inconclusive; -: Negative; *: MT-2 prototipe HTLV-I persistently
infected cell line; **: H9-IIIb prototipe HIV-1 persistently infected cell line.
RESULTS
 Results are shown in tables 3 and 4. Two of 21 healthy blood donors
(group C) with positive reactivity on screening test and HIV-1 Wb
negative resulted in inconclusive IFA on HIV-1 (H9 IIIb) cell line, while
all the serum samples were negative for HTLV-I/II on IFA (Table 3).
Only one out of 11 healthy blood donors (group A) with indeterminate
HIV-1 Wb status was found positive for HIV-1 antibody by IFA. No
anti-HTLV-I/II antibodies were detected in this group by IFA (Table 3).
Table 4
HIV-1 antibodies in individuals with indeterminate HTLV-I/II Wb status
Group n (%) Anti HTLV-I/II Anti HIV-1
IFA (MT-2) IFA (H9) Wb
D 6 (86%) - + +
(n: 7)
High risk 1 (14%) + + +
for infection
E
(n: 13) 13 (100%) - - -
Healthy blood
donors
F 8 (100%) - - -
(n: 8)
Healthy blood
donors
+: Positive; -: Negative; IFA: Indirect Immunofluorescence assay; Wb: Western
blot (Novapath HIV-1 immunoblot BIORAD, USA).
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Furthermore, although cross-reactivities of HIV-1 antisera with
HTLV-I/II antigens have not been reported, the data presented here in
high risk populations with indeterminate HIV-1 and HTLV-I/II Wb results
(Fig. 1 and 2) show serological cross- recognition between HIV-1 proteins
and HTLV-I/II proteins on Wb.
Serological cross-reactivities among many of the lentiviruses have
been reported16. Moreover, MANZARI et al. have reported data showing
cross-reactivity between the sera of patients infected with the human
retrovirus HTLV-V and the HIV-1 p24 core antigen on Wb15.
These results pointed out the need to investigate HTLV-I/II reactivity
in indeterminate HIV-1 samples and viceversa in order to define the
diagnosis.
The high prevalence of HIV and HTLV-I/II in individuals who have
risk factors for retrovirus infection together with the policlonal B-cell
stimulation characteristic of this population, would be other explanation
for the indeterminate patterns. The production of antibodies with cross-
reactivity to epitopes of HIV-1 and cellular proteins after polyclonal
stimulation of B cells has been reported4 .
The individuals with HIV-1 or HTLV-I/II Wb indeterminate results who
were reclassified as seropositive by IFA (Fig. 1 and 2) emphasize the technical
difficulties found in performing available HTLV- HIV confirmatory assays,
specially Wb, and illustrates the potential misclassification of HTLV- HIV
seropositive individuals as seroindeterminate on this assay. Recent data on
HTLV-I seroconverters who were recipients of HTLV-I positive cellular blood
products support the appearance of gag antibodies before seroreactivity to
native env protein12.
It is interesting that indeterminate profiles for HTLV-I/II or HIV-1
on Wb showed no differences between the various studied populations.
Reports on the association of indeterminate HIV-1 Wb profiles with a
positive predictive result should be regarded cautiously3.
Indeed, the present study shows the potential usefulness of IFA in
elucidating the status of HIV-1 and HTLV-I/II infection of individuals
Fig. 2 - A. Interpretation of serologic results in low risk populations with HTLV-I/II indeterminate Western blot profile. Figure designed from group E and F (healthy blood donors). Data
presented in Table 4. B. Interpretation of serologic results in high risk populations with HTLV-I/II indeterminate Western blot profile. Figure designed from group D (high risk individuals for
infection). Data presented in Table 4.
Fig. 1 - A. Interpretation of serologic results in low risk populations with HIV-1 indeterminate Western blot profile. Figure designed from group A (healthy blood donors). Data presented in Table
3. B. Interpretation of serologic results in high risk populations with HIV-1 indeterminate Western blot profile. Figure designed from group B (high risk individuals for infection). Data presented
in Table 3.
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from Argentina with indeterminate Wb profiles, thus enabling resolution
of retrovirus infection status. Moreover, in several countries attempts
for reducing the frequency of indeterminate results are done by using
IFA test, instead of the Wb20. Also, because of its lower cost, this
procedure should be a suitable alternative test for the confirmatory
diagnosis of retrovirus infection in Argentina as well as in other
developing countries.
RESUMO
Parâmetros de reatividade de amostras de soro com resultados
indeterminados por Western blot para anticorpos contra HIV-1 e
HTLV I/II em Córdoba, Argentina
Amostras de soro sangüíneo (n: 110) de indivíduos de
comportamento de risco e doadores de sangue da cidade de Córdoba, na
Argentina, com perfis de reactividade para HIV-1 e HTLV-I/II
indeterminada por Western blot (Wb), foram estudadas para anticorpos
específicos contra HTLV-I/II e HIV-1 por meio do Ensaio de
Imunofluorescência Indireta (IFI). Este estudo foi realizado para
caracterizar as reações putativas com proteínas HIV-1 e HTLV-I/II e
resolver o estado da infecção por retrovírus destes indivíduos. Os
resultados mostram que os soros dos doadores sangüíneos que apresentam
padrões indeterminados para HTLV-I/II e HIV-1 no Wb não são reagentes
contra HTLV-I/II e HIV-1 por IFI. Mas, um alto índice de amostras de
individuos com alto risco com resultado indeterminado no Wb para HIV-
1 e HTLV-I/II apresentaram resultados positivos para HTLV-I/II e HIV-
1 por IFI, respectivamente. Nosso estudo sugere que a reatividade
indeterminada para HTLV-HIV na população de baixo risco deve-se a
uma reação cruzada contra antígenos não virais; e que na população de
alto risco as amostras indeterminadas apresentam reação cruzada entre
as proteínas HIV-1 e HTLV-I/II no Wb. Estes resultados indicam que se
faz preciso pesquisar a reatividade de HTLV-I/II nas amostras
indeterminadas de HIV-1 e vice-versa, para confirmar o diagnóstico.
Por último, este trabalho mostra a utilidade potencial da IFI para
determinar o estado de infecção HIV-1 e HTLV-I/II dos indivíduos com
perfis indeterminados por Wb, permitindo assim, a resolução do estado
real de infecção por retrovírus.
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